Research in the Frank Mason Lab focuses on the causes and consequences of genomic instability in cancer, with a particular emphasis on errors in cell division, chromosomal integrity, and epigenetic dysfunction.
To investigate these problems, we utilize cell biological, biochemical, genetic and genomic approaches in kidney cancer and leukemia cells, as well as mouse and human tumors.
The goal of the Mason Lab is to explicate mechanisms that preserve genome maintenance and cell fitness and identify how these are subverted in cancer to promote therapeutic resistance.
By better understanding the origin and consequences of genomic instability, we aim to identify more targeted vulnerabilities in cancer.
Frank Mason, PhD, left, Kimryn Rathmell, MD, PhD, and their colleagues have identified an early event in the development of cancer, one that could lead to new ways to prevent it.